Trial Profile
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms FANTOM-II
- Sponsors REVA Medical
- 27 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Feb 2024.
- 27 Mar 2023 Status changed from completed to active, no longer recruiting.
- 19 Sep 2022 Status changed from recruiting to completed.